3E5fHvuwC

2013-2014 Diretrizes SBD
poglicemia e DCV, níveis em torno de
7% são mais aceitáveis.
Em conclusão, para reduções primária
e secundária do risco cardiovascular,
persistem as recomendações de
meta < 7% para HbA1c, devendo, contudo,
haver flexibilização e individualização
para cada paciente. As recomendações
das metas de tratamento para
hipertensão e dislipidemia devem ser
enfatizadas. Estatinas e profilaxia com
AAS persistem como pilares na redução
do risco cardiometabólico em pacientes
com diabetes, sendo a cessação
do tabagismo obrigatória.
Referências
1. Kannel WB, McGee DL. Diabetes and
glucose tolerance as risk factors for
cardiovascular disease: The Framingham
Study. Diabetes Care. 1979;
2:120-6.
2. Stratton IM, Adler AI, Neil HA, Matthews
DR, Manley SE, Cull CA et al.
Association of glycaemia with macrovascular
and microvascular complications
of type 2 diabetes (UKPDS
35): Prospective observational study.
BMJ. 2000; 321:405-12.
3. Deedwania PC, Fonseca VA. Diabetes,
pre-diabetes and cardiovascular
risk: Shifting the paradigm. Am J
Med. 2005; 118:939-47.
4. Tuomilehto J, Lindstrom J, Eri ksson
JG, Valle TT, Hamalainen H, IlanneParikka
P et al. Prevention of type 2
diabetes mellitus by chan ges in lifestyle
among subjects with impaired
glucose tolerance. N Engl Med.
2001; 344:1343-50.
5. Lindstrom J, Louheranta A, Mannelin
M, Rastas M, Salminen V, Eriksson
J et al. The Finnish Diabetes Prevention
Study (DPS): Lifestyle intervention
and 3-year results on diet and
physical activity. Diabetes Care.
2003; 26:3230-6.
6. Gaede P, Lund-Andersen H, Par ving
H-H, Pedersen O. Effect of a multifactorial
intervention on mortality
in type 2 diabetes. N Engl J Med.
2008; 358:580-91.
7. Stettler C, Allemann S, Jüni P, Cull CA,
Holman RR, Egger M et al. Glycemic
control and macrovascular disease
in types 1 and 2 diabetes mellitus:
Meta-analysis of randomized trials.
Am Heart J. 2006; 152:27-38.
8. American Diabetes Association. Understanding
Cardiometabolic Risk.
Broadening Risk Assesment and Management.
Clinical Education Program
Series. Disponível em: www.
diabetes.org. Acesso em: 2009.
9. Nathan DM, Cleary PA, Backlund JY,
Genuth SM, Lachin JM, Orchard TJ et
al. Intensive diabetes treatment and
cardiovascular disease in patients
with type 1 diabetes. N Engl J Med.
2005; 353:2643-53.
10. Gerstein HC, Miller ME, Byington RP,
Goff DC Jr, Bigger JT, Buse JB et al.
Action to Control Cardiovascular
Risk in Diabetes Study Group. Effects
of intensive glucose lowe ring in
type 2 diabetes. N Engl J Med. 2008;
358:2545-59.
11. Buse JB, Ginsberg HN, Bakris GL, Clark
NG, Costa F, Eckel R et al. Primary
prevention of cardiovascular diseases
in people with diabetes mellitus:
A scientific statement from the
American Heart Association and the
American Diabetes Association. Circulation.
2007; 115:114-26.
12. UK Prospective Diabetes Study
(UKPDS) Group. Effect of intensive
blood-glucose control with metformina
on complications in overweight
patients with type 2 diabetes
(UKPDS 34). Lancet. 1998; 352:
854-65.
13. Chiasson JL, Josse RG, Gomis R, Hanefeld
M, Karasik A, Laakso M. Acarbose
treatment and the risk of cardiovascular
disease and hypertension
in patients with impaired glucose
tolerance: The STOP-NIDDM trial. JA-
MA. 2003; 290:486-94.
14. Holman RR, Paul SK, Bethel MA, Matthews
DR, Neil HAW. 10-year followup
of intensive glucose control in
type 2 diabetes. N Engl J Med. 2008;
359:1577-89.
15. Selvin E, Marinopoulos S, Berkenblit
G, Rami T, Brancati FL, Powe NR et al.
Meta-analysis: Glycosylated hemoglobina
and cardiovascular disease
in diabetes mellitus. Ann Intern
Med. 2004; 141:421-31.
16. Duckworth W, Abraira C, Moritz T,
Reda D, Emannele N, Reaven PD et
al. Intensive glucose control and
complications in American vete rans
with type 2 diabetes. N Engl J Med.
2009; 360 (2):129-39.
17. Patel A, MacMahon S, Calmers J, Neal
B, Billot L, Woodward M et al.; Advance
Collaborative Group. Intensive
blood glucose control and
vascular outcomes in patients with
type 2 diabetes. N Engl J Med. 2008;
358:2560-72.
18. The Action to Control Cardiovascular
Risk in Diabetes Study Group.
Effects of Intensive Glucose Lowering
in Type 2 Diabetes. N Engl J
Med. 2008; 358:24.
19. Skyler JS, Bergenstal R, Bonow RO et
al. Intensive glycemic control and
the prevention of cardiovascular
events: Implications of the Accord,
Advance and the VA Diabetes Trials.
Diabetes Care. 2009; 32:187-92.
20. Epidemiology of Diabetes Interventions
and Complications (EDIC). Design,
implementation and preliminary
results of a long-term follow-up
of the Diabetes Control and Complications
Trial cohort. Diabetes Care.
1999; 22:99-111.
21. The ORIGIN trial investigators. N Eng
J Med. 2012; 2011 Jun.
137